Jeffrey Rowe Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rowe ZOM stock SEC Form 4 insiders trading

Jeffrey has made over 4 trades of the Zomedica Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 175,000 units of ZOM stock worth $210,000 on 29 November 2018.

The largest trade he's ever made was selling 600,000 units of Zomedica Pharmaceuticals stock on 25 March 2015 worth over $17,400,000. On average, Jeffrey trades about 184,524 units every 216 days since 2014. As of 29 November 2018 he still owns at least 275,000 units of Zomedica Pharmaceuticals stock.

You can see the complete history of Mr. Rowe stock trades at the bottom of the page.

Jeffrey Rowe biography

Jeffrey Mark Rowe serves as Chairman of the Board of the Company. He has over 30 years of experience in the specialty pharmacy industry, Jeff Rowe most recently served as Executive Vice President and board member of Diplomat Inc., the largest independent specialty pharmacy company in the United States. During his tenure with Diplomat, the company grew from a single location with less than US$5 million in revenue, to 16 locations and US$3 billion in sales, and became publicly traded on the New York Stock Exchange. Prior to that, Jeff owned two successful community pharmacies in Genesee County, Michigan. An authority in pharmaceutical operations, Jeff offers critical insights into fundamental business strategies involving accreditation, contracting, cybersecurity and regulation, combined with an expertise in compounding and integrative medicine. He is uniquely qualified to identify process improvements and efficiencies while maintaining compliance and quality standards, for increased revenue, profitability and customer satisfaction. Jeff holds a Bachelor of Pharmacy degree from Ferris State University and has completed many health-related credential courses.

How old is Jeffrey Rowe?

Jeffrey Rowe is 60, he's been the Chairman of the Board of Zomedica Pharmaceuticals since 2019. There are 3 older and 9 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.

What's Jeffrey Rowe's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ZOMEDICA CORP.,, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.

Insiders trading at Zomedica Pharmaceuticals

Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers a Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.

What does Zomedica Pharmaceuticals do?

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Zomedica Pharmaceuticals executives and stock owners

Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Stephanie Laine Morley D.V.M., DVM,
  Consultant
• Bruk Herbst,
  Chief Commercial Officer
• Ann Marie Cotter CPA,
  CFO & Sec.
• Rodney Williams,
  Independent Member
• Thomas Robitaille,
  Independent Director
• Johnny Powers,
  Independent Director
• Christopher MacLeod,
  Independent Director
• Jane Eagleson,
  Independent Director
• Christopher Wolfenberg,
  Director
• Angie Moricz,
  Executive Administrative Assistant
• Bruk Herbst,
  Chief Commercial Officer
• Angy Guerrant,
  Director of Portfolio Management
• Andrea Eberle,
  Senior Marketing Manager
• William MacArthur,
  Executive Member and Chief Medical Officer, Director of Research and Development
• Ann Cotter,
  Chief Financial Officer, Secretary
• Robert Cohen,
  Interim Chief Executive Officer, Director
• Stephanie Morley,
  President, Chief Operating Officer
• Jeffrey Rowe,
  Chairman of the Board
• Kristin Domanski,
  VP of HR
• Nicole Westfall,
  VP of Marketing
• Tony Blair,
  Exec. VP of Operations
• Larry C. Heaton II,
  Pres & CEO
• Robert W. DiMarzo,
  Consultant
• Dr. William Carpenter MacArthur,
  Consultant
• David Eaton,
  VP of Marketing
• Michael Schilk,
  VP of Sales
• Sean Whelan,
  
• Russell Kevin Klass,
  Vice President of Sales
• Rampertab Shameze,
  
• James Le Bar,
  Director
• Adrian Lock,
  VP and General Manager
• Larry C Ii Heaton,
  CEO
• Pamela Nichols,
  
• Anthony K Blair,
  COO
• Peter Donato,
  Chief Financial Officer